The Pharma Letter

Eliquis sales forecast to fall by 15.2% in 2026 as European patent expiry nears

Global sales of Bristol Myers Squibb’s and Pfizer’s drug Eliquis (apixaban) are projected to decline by 15.2% in 2026 due to ...
Seeking Alpha

TAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the First Oral Dissolving Film Anticoagulant

TAIPEI, Feb. 17, 2025 /PRNewswire/ -- TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first Apixaban oral dissolving film (ODF). The study ...
BioSpace

BMS Beats Again Despite Eliquis and Cobenfy Disappointments

Bristol Myers Squibb delivered better than expected fourth quarter earnings, but Eliquis missed expectations while Cobenfy ...
Morningstar

TAHO Pharma Announces Submission of New Drug Application (NDA) to the U.S. FDA for TAH3311 - The World's First Apixaban Oral Dissolving Film - Represents a Transformational ...

TAIPEI, Oct. 1, 2025 /PRNewswire/ -- TAHO Pharmaceuticals Ltd. ("TAHO Pharma") today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ...